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Introduction: Microparticles are elevated in patients after successful cardiopulmonary resuscitation (CPR) and
may play a role in the development of endothelial dysfunction seen in post-cardiac arrest syndrome (PCAS), a life
threatening disease with high mortality. To identify mechanisms of endothelial activation and to develop novel
approaches in the therapy of PCAS, the impact of selenium, a trace element with antioxidative properties, was
characterized in endothelial dysfunction induced by microparticles of resuscitated patients. Additionally, course of
plasma selenium levels was characterized in the first 72 hours post-CPR.
Methods: Endothelial cells were exposed to microparticles isolated of the peripheral blood of resuscitated patients,
and leukocyte-endothelial interaction was measured by dynamic adhesion assay. Expression of adhesion molecules
was assessed by immunoblotting and flow chamber. Blood samples were drawn 24, 48 and 72 hours after CPR for
determination of plasma selenium levels in 77 resuscitated patients; these were compared to 50 healthy subjects
and 50 patients with stable cardiac disease and correlated with severity of illness and outcome.
Results: Microparticles of resuscitated patients enhance monocyte-endothelial interaction by up-regulation of
ICAM-1 and VCAM-1. Selenium administration diminished ICAM-1 and VCAM-1-mediated monocyte adhesion
induced by microparticles of resuscitated patients, suggesting that selenium has anti-inflammatory effects after CPR.
Lowered selenium plasma levels were observed in resuscitated patients compared to controls and selenium levels
immediately and 24 hours after CPR, inversely correlated with clinical course and outcome after resuscitation.
Conclusions: Endothelial dysfunction is a pivotal feature of PCAS and is partly driven by microparticles of resuscitated
patients. Administration of selenium exerted anti-inflammatory effects and prevented microparticle-mediated endothelial
dysfunction. Decline of selenium was observed in plasma of patients after CPR and is a novel predictive marker of ICU
mortality, suggesting selenium consumption promotes inflammation in PCAS.Introduction
The worldwide estimated annual incidence of sudden
cardiac death is in the range of four to five million cases
per year. Despite improved treatment, median survival
rate to hospital discharge remains low, from 8 to 18% [1,2].
The poor prognosis of patients after cardiopulmonary
resuscitation (CPR) is caused by a post-cardiac arrest
syndrome (PCAS), a combination of brain injury, circulatory* Correspondence: katrin.fink@uniklinik-freiburg.de
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[3,4]. Important steps in the pathogenesis of PCAS
are the release of reactive oxygen species (ROS) and
endothelial-leukocyte interaction [5], resulting in a
systemic inflammatory response [5,6], endothelial activation
and injury [7-9] and coagulation abnormalities [7,10].
Microparticles (MPs) are small vesicles (0.1 to 1.5 μM)
[11] that originate from vesiculation of the cell membrane
of most eukaryotic cells undergoing activation or
apoptosis [12], thereby expressing antigens characteristic
of their cell of origin [13]. MPs are considered to act as
diffusible messengers [14] to transport bioactive agents
and seem to have gene-regulatory function [15]. MPs mayis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cell-cell interactions [12]. They are able to activate
platelets, leukocytes and endothelial cells [17,18] and
are known to participate in a variety of intercellular
adhesion processes [17] and to induce endothelial
dysfunction [19,20]. Recently our group has shown
that resuscitated patients show substantially increased
levels of different microparticles [8,21] and that those
microparticles may contribute to the pathogenesis of
PCAS by induction of endothelial apoptosis [21].
Selenium is a nutritional trace element essential for
various aspects of human health, exerting its effects
mainly through its incorporation into selenoproteins.
Furthermore, selenium has been reported to modulate
cytokine-induced expression of adhesion molecules on
endothelial cells [22,23]. Accordingly, selenium deficiency
enhances neutrophil adhesion to endothelial cells [24].
Numerous studies report protective effects of selenium
against ischemia/reperfusion injury [25-27] by reduction
of ROS, thus decreasing the inflammatory and endothelial
reactions [27].
Critically ill patients who suffer from severe oxidative
stress exhibit low selenium plasma levels [28,29].
Supporting this notion, selenium substitution has been
shown to reduce mortality in patients with severe sepsis
or septic shock [30,31].
The objective of the present study was to determine
the impact of microparticles of patients after successful
cardiopulmonary resuscitation on endothelial cells ex vivo
and to test the hypothesis that selenium may exert
endothelial protective effects. Furthermore we aimed
to characterize the time course of plasma selenium
concentrations in resuscitated patients. We hypothesized
that decrease in plasma selenium levels may contribute to
development of post-cardiac arrest syndrome, organ
failure and adverse outcome.
Material and methods
Isolation of circulating MPs from resuscitated patients
and healthy volunteers
Microparticles were isolated out of 25 mL of whole
blood collected in citrated tubes from resuscitated
patients 24 hours after return of spontaneous circulation
(ROSC), or healthy subjects, respectively. Samples were
drawn slowly, handled carefully and were processed
immediately after sampling. In the case of venipuncture,
we used a 21-gauge butterfly needle and discarded the
first 7.5 mL. If available, blood was drawn from an arterial
or central venous catheter.
MP isolation was performed according to the protocol
of Boulanger et al. [32]. In brief, platelet-free plasma was
obtained by centrifugation at 11,000 g for two minutes
and was subjected to further centrifugation at 13,000 g for
45 minutes. After resuspension of the MP pellets 100 μLof RPMI medium (containing Hepes and L-glutamine,
from Lonza, Verviers, Belgium) was added and samples
were frozen at −80°C until further analysis. Supernatants,
containing the corresponding microparticle-free dilution
of subjects, were also stored at −80°C and served as
negative controls. MP protein content was assessed by
Bio-Rad Protein Assay (Bio-Rad Laboratories GmbH,
Munich, Germany) and adjusted to the same values for
each subgroup in the experiments. Protein content of
pellets and microparticle-free supernatant did not differ in
resuscitated patients (MP: 15.54 ± 2.581 versus super-
natant: 17.08 ± 2.202 μg/μL, P = 0.6540 (not significant))
and healthy controls, suggesting a comparability of each
pellet with its corresponding supernatant.
Cell culture of human umbilical vein endothelial cells
(HUVECs)
HUVECs were obtained from PromocellTM (Heidelberg,
Germany). The cells were cultured in endothelial cell
growth medium advanced (Provitro, Berlin, Germany),
containing 10% fetal calf serum (FCS), Heparin (22.50 μg),
human recombinant epidermal growth factor (5 ng),
human recombinant fibroblast growth factor (10 ng),
human recombinant vascular endothelial growth factor
(0.5 ng), human recombinant insulin-like growth factor-1
(20 ng), ascorbic acid (1 μg), hydrocortisone (0.20 μg),
gentamicin (50 μg), L-glutamine (2 mmol), and cell cul-
ture plastic was from Nunc (Rolkilde, Denmark). Cultures
were kept at 37°C in a 5% CO2 humidified atmosphere.
Monocytes
After approval from the ethics committee of our institution
(EK-Freiburg 10015/12), monocytes were isolated from
buffy coat leukocytes or citrated human blood from healthy
volunteers. Monocytes were isolated by Ficoll (Biocoll
Separating Solution, Biochrom, Berlin, Germany) gradient
centrifugation and plastic adhesion. Cells were mixed 1:1
(in case of blood separation) or 1:5 (in case of buffy coat
separation) with PBS (Lonza, Veriers, Belgium). After cen-
trifugation at 800 × g for 20 minutes at room temperature
the intermediate layer of cells was removed and
washed with PBS. Cells were maintained in RPMI
medium (Invitrogen, Paisley, UK) with 10% FCS, 1% non-
essential amino acids, 2 mmol L-glutamine, 100 U/mL
penicillin and 100 μg/ mL streptomycin.
Antibodies and reagents
The following fluorescence-labelled antibodies were used:
anti-human ICAM-1 (CD54) antibody (R&D Systems,
Minneapolis, MN, USA); anti-human VCAM-1 (CD106)
antibody (R&D System); anti-mouse IgG1 Cy2 secondary
antibody (for ICAM-1) (Acris Antibodies, Herford,
Germany) and anti-mouse IgG Cy3 secondary antibody
(for VCAM-1) (Jackson ImmunoResearch Laboratories,
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blot were: anti-human ICAM-1 (CD54) antibody (Cell
Signaling Technologies, Danvers, MA, USA); anti-human
VCAM-1 (CD106) antibody (Santa Cruz Biotechnology,
Dallas, Texas, USA); secondary anti-mouse IgG-HRP
antibody (R&D Systems) and secondary anti-rabbit
IgG-HRP antibody (R&D Systems, Minneapolis USA).
VybrantTM carboxyfluorescein-diacetate (CFDA) (Invitrogen,
Darmstadt, Germany) was used for staining of mono-
cytes in flow chamber experiments.Dynamic adhesion assay and endothelial blocking by
selenium
HUVECs were grown in 35-mm dishes (Costar,
Bethesda, MD, USA) to 100% confluence. The Glycotech
(Gaithersburg, MD, USA) flow chamber was assembled
with the dish as the bottom of the resulting parallel flow
chamber. The chamber and tubes were filled with PBS
prior to the experiment. Subsequently, isolated human
monocytes were applied with a syringe and shear stress
was induced with a syringe pump (Harvard apparatus
PHD2000, Holliston, MA, USA) with a flow rate of 0.25
dyne/cm2 (venous flow) for a total of 10 minutes, and then
with 15 dyne/cm2 (arterial flow) for 1 minute. Monocytes
were allowed to adhere to the endothelial cell layer
after pre-treatment of HUVECs for 6 h either with
microparticles of resuscitated or healthy subjects, or
with the cell free supernatant of resuscitated patients,
respectively. In case of selenium treatment HUVECs
were pre-incubated with 1.5 μM selenium for 24 h
additionally.
Adherent cells were quantified under the microscope
and monocytes were visualized by CFDA staining (500 μL
CFDA per 70*106 monocytes, incubated for 15 minutes at
37°C in a water bath). Data from at least four different
experiments were analyzed.Immunocytochemistry
HUVECs were seeded on glass coverslips. Cells were
incubated for 6 h with microparticles from resuscitated or
healthy subjects, or with the cell free supernatant of
resuscitated patients, respectively. Cells were fixed in
ice-cold methanol/acetone at −20°C for 10 minutes
and were blocked with 10% donkey serum for 30 minutes
at room temperature. Subsequently HUVECs were
incubated with an anti-human ICAM-1, or VCAM-1
antibody (both from R&D Systems) and an anti-mouse
IgG1 Cy2 secondary antibody for ICAM (Acris Antibodies
GmbH), or an anti-mouse IgG Cy3 secondary antibody
for VCAM (Jackson ImmunoResearch Laboratories Inc.),
respectively. In the case of selenium treatment HUVECs
were additionally pre-incubated with 1.5 μM selenium
for 24 h.Western blot
HUVECs were stimulated for 6 h with microparticles
from resuscitated or healthy subjects, or with the cell
free supernatant of resuscitated patients, respectively, in
endothelial cell growth medium (Provitro) with 10%
fetal bovine serum (FBS). Cell lysates were resolved
on a reducing polyacrylamide gel, plotted onto a
nitrocellulose membrane (Amersham GE Healthcare,
Pittsburgh, PA, USA) and blocked with 3% non-fat
milk in PBS/Tris with 0.1% Tween 20 for 2 h at
room temperature (20 to 22°C). The membrane was
then incubated with primary antibody overnight at 4°C.
After 1 h of incubation with the secondary antibody,
proteins were visualized using ECL reagent (Amersham
GE Healthcare). Densitometric analysis of western blots
was performed using Quantity One 1-D Analysis Software
Version 4.4 (Bio-Rad Laboratories GmbH, Munich,
Germany). All western blots were repeated at least three
times and quantified data are shown.
Measurement of plasma selenium levels
For measurements of selenium plasma levels 2 to 3 mL
of whole blood were collected in EDTA tubes every 24 h
from day one to three after ROSC (day 1, 2, 3). Samples
were stored at −20°C. Measurements of selenium con-
centrations were performed blinded by staff in the la-
boratories of Biosyn (Fellbach, Germany) by electrothermal
atomic absorption spectrometry using a spectrometer
equipped with a Zeeman effect background correction
(5100 PC, Perkin-Elmer, Paris, France).
Samples for measurement of routine indicators of organ
dysfunction/failure (for example, creatinine, diuresis,
bilirubin, albumin, platelet count, blood pressure,
catecholamine doses, or arterial pressure of oxygen/
inspired oxygen fraction (paO2/FiO2) were simultaneously
collected. Measurements were performed in the laborator-
ies of the University hospital of Freiburg using automated
measures.
Patient recruitment
After the institutional approval of the Ethics Committee
of Albert Ludwigs University (EK-Freiburg 328/09) we
took blood samples for microparticle isolation from a total
of 77 patients who underwent CPR after cardiac arrest
from any cause. All patients were treated according to the
international guidelines given by International Liaison
Committee on Resuscitation in 2008 [4]. Results
were compared with 50 healthy subjects without any
cardiovascular risk who were taking no medication.
Because lowered selenium plasma levels are described
in patients with coronary artery disease (CAD) [33,34]
we chose a second cardiac control group to exclude
possible effects on selenium levels caused by underlying



























Figure 1 Microparticles from resuscitated patients enhance
monocyte-endothelial interaction under flow conditions.
Stimulation of human umbilical vein endothelial cells (HUVECs) with
microparticles from resuscitated patients (black bars) leads to
enhanced monocyte-endothelial interaction under venous flow
(left and middle), and firm adherence under arterial flow (right)
conditions in the dynamic adhesion assay, compared to microparticle-
free supernatant from resuscitated patients (dark gray bars) and
stimulation with microparticles from healthy subjects (light gray bars):
***P <0.0001; **P <0.001; #P <0.05; ns = not statistically significant). CPR,
cardiopulmonary resuscitation; ICAM-1, intracellular adhesion molecule-1;
VCAM-1, vascular cell adhesion molecule-1.
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logical ward for any reason for measurements of selenium
plasma levels.
Inclusion and exclusion criteria
Inclusion criteria were CPR following cardiac arrest due
to any cause, occurring in or out of hospital, and with a
duration of at least five minutes. Resuscitation was
performed according to the European Resuscitation
Council Guidelines for Resuscitation [4]. Patients with
malignant diseases were excluded from the study, because
elevation of MPs has been reported to be increased in
various malignancies [35]. Similarly, patients younger than
18 years, pregnant patients, patients with sepsis or severe
inflammation or trauma patients were excluded, because
alterations in plasma selenium levels have already been
described in these patients [36]. Informed consent
was obtained post hoc from patients surviving with
good neurological outcome or from their relatives in
the case of non-surviving patients. Informed consent
was given by all patients in the control group. All
patients received micronutrient supplementation con-
taining 0.032 mg per day of selenium, no later than
24 h after admittance to the ICU. Twenty-three patients
had to be excluded retrospectively because of selenium
administration (1000 μg daily) in the first 72 h after CPR.
Data collection
Baseline characteristics were recorded including age,
gender, concomitant diseases and cardiovascular risk
profile. In resuscitated patients data on cardiac arrest
and cardiopulmonary resuscitation were registered and
severity of disease was evaluated by sequential organ
failure assessment (SOFA) [37]. The SOFA score was
calculated daily and the maximum SOFA score was
defined as the highest score reached during the first
3 days of the ICU stay.
Statistical analysis
Continuous variables are expressed as mean ± standard
error of the mean (SEM). Because data for CPR, control
patients and healthy subjects were normally distributed,
they were compared by Student’s t-test. Correlations
between selected variables were estimated by Spearman-rho
test and the corresponding R2 was calculated. The predictive
value of plasma selenium concentrations on ICU outcome
was calculated using a receiver operating characteristic
(ROC) curve and the area under the curve (AUC) was com-
puted and analyses were performed with SPSS version 19.0
(SPSS Inc., Chicago, IL, USA). In flow chamber experiments
a correction for multiple testing was made by two-way
repeated-measures analysis of variance (ANOVA) with
post-test Bonferroni correction, including an all-pair-wise
comparison. Basic data and outcomes were compared bychi-quadrate test, Fisher’s exact test, and Student’s t-test, re-
spectively. Statistical significance was defined as a two-tailed
P-value <0.05.
Results
Microparticles of resuscitated patients enhance
monocyte-endothelial interaction under flow conditions
To assess the impact of MPs from resuscitated patients
on endothelial inflammation, cultured HUVECs were
exposed to MPs and monocyte-endothelial adhesion was
quantified under physiological flow conditions. Supporting
the notion that MPs mediate inflammatory effects, endo-
thelial cell exposed to MPs from resuscitated patients
increased monocyte adhesion to endothelial cells compared
to exposure to the corresponding microparticle-free super-
natant of each MP sample from CPR patients in a dynamic
adhesion assay (after 5 minutes: MP: 0.38 ± 0.05 versus
supernatant: 0.24 ± 0.04 adherent monocytes per HUVEC,
P = 0.02; after 10 minutes: MP: 0.64 ± 0.09 versus
supernatant: 0.39 ± 0.05 adherent monocytes per HUVEC,
P = 0.02 and after 1 minute of arterial flow: MP: 0.47 ± 0.04
versus supernatant: 0.28 ± 0.06, P = 0.01).
Additionally MPs from resuscitated patients augmented
monocyte adhesion 2.4-fold when compared with the effect
of MPs from healthy subjects (after 5 minutes: healthy:
0.14 ± 0.05 adherent monocytes per HUVEC, P = 0.009;
after 10 minutes: healthy: 0.26 ± 0.09, P = 0.01 and after
1 minute of arterial flow: healthy: 0.14 ± 0.05, P = 0.0009)
(Figure 1).
Taken together these data suggest that MPs from resus-
citated patients enhance monocyte-endothelial interaction
under flow conditions.
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expression of endothelial adhesion molecules
To evaluate the molecular mechanisms leading to the
increase in monocyte adhesion to the endothelium
following exposure to MPs of resuscitated patients,
we investigated expression of ICAM-1 and VCAM-1
after stimulation of HUVECs with MPs. Both immuno-
cytochemistry and western blot experiments revealed that
endothelial cell exposure to MPs of CPR patients
increased the levels of ICAM-1 expression of endothelial
cells (Figure 2), compared to MP-free supernatant and
MPs from healthy subjects.
Consistent with regulation of ICAM-1 endothelial cell
exposure to MPs from CPR patients increased the levels
of VCAM-1 expression of endothelial cells, shown by
immunocytochemistry and western blot experimentsFigure 2 Microparticles from resuscitated patients increase expressio
adhesion molecule-1 (VCAM-1) on endothelial cells. (A, B) Increased IC
endothelial stimulation with microparticles (black bars on the right in each
patients (gray bars; right), shown by western blot analysis and compared w
graph) and microparticle-free supernatant (gray bars; middle) from healthy
panel. (C) Increased ICAM-1 (panels on the left; green staining by Cy2) and
after human umbilical vein endothelial cell (HUVEC) stimulation with micropa
shown by immunocytochemistry, compared with microparticle-free supernat
(upper left panels): 4,6-Diamidino-2-phenylindole (DAPI) was used for staining(Figure 2). As expected, MP-free supernatant, as highly
diluted plasma solution did not significantly enhance
ICAM-1 and VCAM-1 expression at the endothelium side.
These findings suggest that adhesion molecules ICAM-1
and VCAM-1 participate in MP-induced endothelial
monocyte interaction.
Selenium reduces monocyte adhesion to the endothelium
under flow conditions
The increased interaction of monocytes to the endothe-
lium after stimulation with MPs from CPR patients in
the dynamic adhesion assay can be completely blocked by
pre-treatment of endothelial cells with selenium under ven-
ous flow (after 5 minutes, no selenium, 0.18 ± 0.02 versus
selenium, 0.05 ± 0.01 adherent monocytes per HUVEC,
P = 0.0004; after 10 minutes, no selenium, 0.31 ± 0.05n of intracellular adhesion molecule-1 (ICAM-1) vascular cell
AM-1 (left panels) and VCAM-1 (right panels) protein expression after
graph) compared with microparticle-free supernatant from resuscitated
ith stimulation with microparticles (black bars in the middle of each
subjects. Positive and negative controls are shown on the left in each
VCAM-1 (panels on the right; red staining by Cy3) protein expression
rticles from resuscitated patients (lower right panels in each illustration),
ant from resuscitated patients (lower left panels) and negative control
of nuclei. (**P <0.001; *P <0.01). CPR, cardiopulmonary resuscitation.
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of arterial flow (no selenium, 0.22 ± 0.04 versus selenium,
0.05 ± 0.01, P = 0.001) (Figure 3).
This result demonstrates that selenium reduces monocyte
adhesion to the endothelium under physiological flow
conditions.
Selenium administration reduces expression of
endothelial adhesion molecules after stimulation with MP
of resuscitated patients
To evaluate if reduced monocyte adhesion is a consequence
of reduced expression of adhesion molecules, we tested
ICAM-1- and VCAM-1- expression of MP-stimulated
endothelial cells after selenium administration. The
augmented expression of the endothelial adhesion
molecules ICAM-1 and VCAM-1 after stimulation of
endothelial cells with MPs from CPR patients can be
completely blocked after selenium pre-treatment, shown
by immunocytochemistry and western blot experiments
(Figure 4).
Taken together selenium administration reduces expres-
sion of endothelial adhesion molecules of endothelial cells
stimulated with MP of resuscitated patients.
Selenium plasma levels are diminished in resuscitated
patients
To assess the role of selenium in post cardiac arrest
syndrome, levels of selenium were quantified in patients
(n = 77) after successful cardiopulmonary resuscitation. As
shown in Table 1 baseline characteristics of resuscitated
patients are comparable to those published in other
studies in view of age, duration and cause of CPR, severity
of illness and outcome parameters.
All measurements were also performed in 50 healthy


























Figure 3 Selenium administration reduces monocyte adhesion
to the endothelium under flow conditions. Addition of selenium
on human umbilical vein endothelial cells (HUVECs) diminished
microparticles-induced monocyte-endothelial interaction (crosshatched
bars) after stimulation with microparticles from resuscitated patients
under venous flow (left and middle), as well as firm adherence under
arterial flow (right) conditions in dynamic adhesion assay, compared
with unblocked stimulation with microparticles from resuscitated
patients (black bars) and to microparticle-free supernatant from
resuscitated patients (dark gray bars). (**P <0.001; *P <0.01).of 30.4 ± 1.4 years. Selenium plasma levels were also
compared to a cardiac control group consisting of 50
patients that were comparable in baseline characteristics.
Resuscitated patients had the lowest plasma selenium
concentrations at study inclusion compared to healthy
subjects (86.0 ± 2.9 versus 109.1 ± 1.3 μg/L; P <0.0001 and
compared to the cardiac controls (versus 94.2 ± 2.2 μg/L;
P = 0.04). Plasma selenium concentrations persisted
low on the second (84.8 ± 2.9 μg/L) and third day
(82.1 ± 3.1 μg/L) after ROSC compared to cardiac
control patients (day 2: P = 0.02; day 3: P = 0.047) or
healthy subjects (day 2: P <0.0001; day 3: P <0.0001)
(Figure 5).
Decline of plasma selenium in resuscitated patients is
associated with severity of disease and poor outcome
Resuscitated patients who survived the ICU stay (survivors)
had significantly higher plasma selenium levels at admission
(98.1 ± 4.5 versus 75.6 ± 3.4 μg/L; P = 0.0007) and on the
third day after CPR (89.9 ± 4.9 versus 74.1 ± 3.4 μg/L;
P = 0.048)., Accordingly ICU non-survivors had sig-
nificantly lower plasma selenium levels compared to
both control groups at all time points (versus cardiac con-
trols: day 1 P = 0.00047; day 2 P = 0.003; day 3 P = 0.0006;
and healthy days 1 to 3: P <0.0001) (data not shown).
Plasma selenium concentrations of resuscitated patients
measured within the first hours after CPR (day 1) had
predictive power in identifying ICU mortality computing
the area under the curve (AUC) of a receiver operating
characteristic (ROC) (AUC= 0.665, P <0.05) (Figure 6).
Furthermore, the minimum plasma selenium concentra-
tion was inversely correlated to the maximal degree of
organ dysfunction/failure during the ICU stay as assessed
by the maximum SOFA score (R2 = 0.27, P <0.05) (data not
shown). Taken together, reduced selenium plasma levels in
resuscitated patients in the post-resuscitation period are
associated with severity of disease and poor outcome.
Discussion
In the present study we demonstrate that microparticles
of patients after successful cardiopulmonary resuscitation
cause enhanced monocyte adhesion to the endothelium
that is partly mediated by enhanced expression of the
endothelial adhesion molecules ICAM-1 and VCAM-1.
Both effects can be blocked by selenium administration,
suggesting a potential therapeutic approach for selenium
in post-cardiac arrest syndrome. Furthermore selenium
plasma levels were lowered in resuscitated patients,
particularly in ICU non-survivors and selenium levels
have predictive value in identifying ICU mortality.
In PCAS whole body ischemia/reperfusion leads to
enhanced endothelial inflammation reflected by endothelial-
leukocyte interactions [7,6], resulting in increased micro-
vascular permeability and, hence, loss of endothelial
Figure 4 Selenium administration reduces expression of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) after stimulation with microparticles. (A, B) Addition of selenium on human umbilical vein endothelial cells (HUVECs)
diminished microparticle-induced ICAM-1 (left panels) and VCAM-1 (right panels) protein expression (checkered bars in each panel), shown by
western blot analysis, compared with unblocked stimulation with microparticles or supernatant (black bars) from resuscitated patients (on the
right in each panel) healthy controls (on the left), respectively. (C) Addition of selenium on HUVECs diminished microparticle-induced ICAM-1
(left panels; green staining by Cy2) and VCAM-1 (right panels; red staining by Cy3) protein expression after HUVEC stimulation with microparticles from
resuscitated patients (lower right panels in each illustration), shown by immunocytochemistry, compared with unblocked stimulation with microparticles
from resuscitated patients (lower left panels): 4,6-Diamidino-2-phenylindole (DAPI) was used for staining of nuclei. (**P <0.001; *P <0.01).
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MPs directly affect the endothelium [20] and MPs isolated
from patients with septic shock, or acute myocardial infarc-
tion cause endothelial dysfunction or apoptosis [19,39].
Our group recently described elevated endothelial-derived
MPs in patients after CPR [8,21] and that these MPs may
also enhance endothelial apoptosis [21]. Therefore, in the
present study, we aimed to investigate the influence of MPs
on the endothelium and monocyte-endothelial interaction
ex vivo. Hereby we identify MPs of resuscitated patients to
enhance monocyte adhesion to endothelial cells under
physiologic flow conditions. This bond seems to be a fore-
most tight adherence, as most of the monocytes remained
bound even under arterial flow conditions.Binding is realized by enhanced ICAM-1 and VCAM-1
expression on the endothelium after exposure to
MPs of CPR patients, proven by western blot and
immunocytochemistry results. Barry et al. had already
reported in 1998 that platelet MPs are able to increase
monocyte adherence to endothelial cells by upregulation
of adhesion molecules on both cell types [40]. Recently,
the TIDE study presented evidence for different patterns
of acute coronary occlusion with increased intracoronary
concentrations of endothelial-derived MPs in patients
suffering from cardiac arrest [41]. Unfortunately in the
present study, we did not assess the MP subtypes,
therefore a distinction of the action of specific subtypes of
MPs generated during and after CPR is not possible.
Table 1 Baseline characteristics of resuscitated and control patients





Number % Number % (versus CPR) Number % (versus CPR)
Age (years) 64.7 ± 1.9 69.9 ± 1.7 <0.05 30.4 ± 1.4 <0.001
Gender Male 59 77.6 33 66.7 0.22/ ns 24 48.0 <0.01
Female 18 23.4 17 33.3 26 52.0
Cause of cardiac arrest/hospital
admission
Cardiac 58 75.3 50 100.0 <0.005
Non cardiac 15 19.5 0 0.0
Unknown 4 5.2 0 0.0
Medical history CAD 52 67.5 41 82.0 0.10/ ns 0 0.0 <0.001
Coronary angiography 58 75.3 35 70.0 0.54/ ns
PCI 39 50.6 22 44.0 0.47/ ns
Duration of CPR (minutes) 24.5 ± 4.9
Estimated duration of asphyxia
(minutes)
3.3 ± 0.5
Initial rhythm VT/ VF 49 63.6
Asystole/ PEA 28 36.4
Outcome Survival to discharge 41 53.2 48 96 <0.001
Length of ICU stay 7.6 ± 0.7
GOS at discharge 4.2 ± 0.2 5.5 ± 0.0 <0.001









Table 1 shows the clinical characteristics of all resuscitated patients (n = 77), cardiac control patients (n = 50) and healthy controls (n = 50) that were included into
measurement of plasma selenium levels. Cause of cardiac arrest was defined as any underlying cardiac disease leading to cardiac arrest, or hospital admission,
respectively (for example, coronary artery disease (chronic or acute), heart failure, rhythmic disturbances). CPR, cardiopulmonary resuscitation; CAD, coronary
artery disease; PCI, percutaneous coronary intervention; VT, ventricular tachycardia; VF, ventricular fibrillation; PEA, pulseless electrical activity; GOS, Glasgow
outcome scale; SOFA, sequential organ failure assessment; ROSC, return of spontaneous circulation.
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cules in response to MPs may be due to internalization of
MPs by endothelial cells, thereby inducing expression of
cell adhesion molecules and activation of the nuclear
factor-κB [42]. However, isolated MPs from human athero-
sclerotic plaques have also been shown to transfer ICAM-1
directly to endothelial cell membranes [43]. Accordingly,
we could not detect enhanced mRNA expression of endo-
thelial adhesion molecules after MP stimulation (data not
shown)], which is in line with the literature available [43].
Nevertheless, the precise mechanism of increased ICAM-1
and VCAM-1 expression in endothelial cells exposed to
MP of resuscitated patients was not addressed in the
present study. To exclude effects of any compounds occur-
ring in the dilution of the MP pellets, we chose supernatant
of pelleted MPs as an internal control.
As selenium has been shown to inhibit cytokine-induced
expression of endothelial adhesion molecules [22], thus
reducing leukocyte adhesion to the endothelium [44], wefocused on selenium as a potential therapeutic approach in
this setting. Indeed selenium administration significantly
reduced monocyte adhesion to HUVECs stimulated by
MPs from resuscitated patients, thereby protecting
endothelial cells from MP-related activation. At the
cellular level we demonstrated that selenium administra-
tion may inhibit the upregulation of endothelial adhesion
molecules ICAM-1 and VCAM-1 caused by MPs of
resuscitated patients. Other possible mechanisms of
reduced leukocyte-endothelial interaction after selenium
administration, such as downregulation of monocyte
adhesion molecules were not addressed in the present
study.
As decreased plasma selenium concentrations occur in
severely ill ICU patients [28,29], we were interested in
selenium plasma levels of patients after successful CPR.
Actually, resuscitated patients exhibited significantly lower
plasma selenium concentrations compared to healthy sub-


























Figure 5 Lowered selenium plasma levels in resuscitated patients.
Selenium plasma levels (measured by electro thermal atomic absorption
spectrometry) of patients after cardiopulmonary resuscitation (CPR) are
reduced in the first 72 hours after CPR (black bars; 24 hours: CPR day 1,
48 hours: CPR day 2, 72 hours: CPR day 3), compared with patients with
stable cardiac disease (gray bar; coronary artery disease (CAD)) and
healthy subjects (white bar; Healthy). (***P <0.0001; ##P <0.005).
Fink et al. Critical Care  (2015) 19:58 Page 9 of 11disease. Plasma levels were lowest at study inclusion but
remained low up to 72 hours after ROSC. According to
the literature decreased plasma selenium concentrations
are found in patients with systemic inflammation [29],
including surgical [36] and trauma patients [45].
Interestingly, patients undergoing cardiac surgery, most
closely resembling whole body ischemia/reperfusion













Figure 6 Plasma selenium levels on day 1 are a predictive
marker of ICU mortality. Plasma selenium concentrations of
resuscitated patients measured within the first 24 hours after
cardiopulmonary resuscitation had predictive power in identifying
ICU mortality (computing the area under the curve (AUC) = 0.665 of
a receiver operating characteristic (ROC).levels [29,46]. Additionally, low selenium blood levels in
this study were an independent predictor for the postoper-
ative development of multiorgan failure [46] and reduced
plasma selenium concentrations were associated with
increased ICU mortality in critically ill patients [29,36].
Our study revealed comparable results in resuscitated
patients, as ICU non-survivors exhibited significantly
lower plasma selenium levels compared to ICU survivors
at all time points. Moreover, plasma selenium concentra-
tions of resuscitated patients at admission to the ICU
were predictive in identifying ICU mortality after CPR
and were related to organ dysfunction/failure assessed
by the SOFA score. This is in line with other publica-
tions showing a comparable inverse correlation of sel-
enium levels to acute physiology and chronic health
evaluation (APACHE) II score, simplified acute physi-
ology score (SAPS) II and SOFA scores in critically ill
patients [36].
Mechanistically, antioxidant properties of selenium
incorporated into selenoproteins, such as glutathione
peroxidase (GPx) [47], are exhibited by mitigating tissue
damage caused by ROS [48,49]. It is well established GPx
activity parallels serum selenium levels [50,51] and
selenium deficiency is associated with subnormal levels of
selenoproteins [52]. Accordingly, randomized controlled
trials and recent meta-analyses showed that high-dose
selenium treatment is effective in reducing mortality rates
in critically ill patients [53], as well as patients with
severe sepsis or septic shock [30,54,55]. Interestingly,
no selenium-specific side effects were observed in
several studies, even in high-dose selenium treatment
[30,56]. Regarding the present data, one might specu-
late that selenium supplementation might improve
survival and/or clinical course of patients after successful
CPR, but this has to be addressed in randomized
controlled trials.
A certain limitation of the present study might be the
comparison of critically ill patients after CPR with
healthy subjects. As there is an association between low
selenium status and coronary artery disease [33,34], we
aimed to exclude possible effects on selenium levels
caused by CAD in the resuscitation group by choosing a
second control group of patients with stable cardiac
disease, presenting mostly CAD. It must however be
mentioned that resuscitated patients were not matched
with the cardiac control group, which limits the strength
of the evidence.
Conclusion
The present study provides evidence of the pathophysio-
logical relevance of microparticles in post-cardiac arrest
syndrome, as they strongly alter endothelial and vascular
function and may translate ischemia/reperfusion injury into
a systemic process. Selenium plasma levels in resuscitated
Fink et al. Critical Care  (2015) 19:58 Page 10 of 11patients are predictive of patients’ clinical course and
outcome after cardiopulmonary resuscitation. For the
first time we identify selenium administration as a possible
therapeutic approach by mitigating endothelial activation
in post-cardiac arrest syndrome.
Key messages
 Microparticles isolated from patients after
cardiopulmonary resuscitation enhance monocyte
adhesion to endothelial cells ex vivo by upregulation
of ICAM-1 and VCAM-1 on endothelial cells
 Selenium administration moderated
microparticle-mediated monocyte-endothelial
interaction and upregulation of ICAM-1 and
VCAM-1 on endothelial cells, thereby
exhibiting anti-inflammatory effects
 Patients after successful cardiopulmonary resuscitation
exhibit lowered selenium plasma levels compared to
healthy subjects and patients with cardiac disease
 Plasma selenium levels of resuscitated patients
inversely correlated with severity of disease and
outcome in the post-arrest period and were shown
to be a predictive marker of ICU mortality
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